GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (STU:TQ80) » Definitions » Enterprise Value

Theratechnologies (STU:TQ80) Enterprise Value : €151.82 Mil (As of May. 07, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Theratechnologies Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theratechnologies's Enterprise Value is €151.82 Mil. Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2025 was €6.70 Mil. Therefore, Theratechnologies's EV-to-EBIT ratio for today is 22.67.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Theratechnologies's Enterprise Value is €151.82 Mil. Theratechnologies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2025 was €9.24 Mil. Therefore, Theratechnologies's EV-to-EBITDA ratio for today is 16.43.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Theratechnologies's Enterprise Value is €151.82 Mil. Theratechnologies's Revenue for the trailing twelve months (TTM) ended in Feb. 2025 was €82.70 Mil. Therefore, Theratechnologies's EV-to-Revenue ratio for today is 1.84.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Theratechnologies's Enterprise Value is €151.82 Mil. Theratechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2025 was €-16.75 Mil. Therefore, Theratechnologies's EV-to-FCF ratio for today is -9.07.


Theratechnologies Enterprise Value Historical Data

The historical data trend for Theratechnologies's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Enterprise Value Chart

Theratechnologies Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 177.15 278.79 230.49 83.84 83.56

Theratechnologies Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.57 73.04 67.79 83.56 113.14

Competitive Comparison of Theratechnologies's Enterprise Value

For the Biotechnology subindustry, Theratechnologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Enterprise Value falls into.


;
;

Theratechnologies Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Theratechnologies's Enterprise Value for the fiscal year that ended in Nov. 2024 is calculated as

Theratechnologies's Enterprise Value for the quarter that ended in Feb. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (STU:TQ80) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Theratechnologies's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=151.820/6.697
=22.67

Theratechnologies's current Enterprise Value is €151.82 Mil.
Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Theratechnologies's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=151.820/9.242
=16.43

Theratechnologies's current Enterprise Value is €151.82 Mil.
Theratechnologies's EBITDA for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.24 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Theratechnologies's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=151.820/82.701
=1.84

Theratechnologies's current Enterprise Value is €151.82 Mil.
Theratechnologies's Revenue for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €82.70 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Theratechnologies's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=151.820/-16.747
=-9.07

Theratechnologies's current Enterprise Value is €151.82 Mil.
Theratechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies Enterprise Value Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Theratechnologies Headlines

No Headlines